Yarrow Bioscience, Inc.: 5%+ holders

As of November 7, 2026, 11 holders' latest Schedule 13D or 13G filings report owning 5% or more of Yarrow Bioscience, Inc. The largest reported stake is Logos Global Management LP's, at 10.7%. 21 filings are on record since August 14, 2025 (Schedule 13G/A, August 7, 2026).

venBio Global Strategic Fund V, L.P. also filed stake reports on 1 other company ↓

Sell to companies like Yarrow Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-07 · Reporting person: Bellevue Group AG · Sole voting: 0 · Shared voting: 1,000,000 · Sole dispositive: 0 · Shared dispositive: 1,000,000 · SCHEDULE 13G, 2026-10-07
• Filed 2026-09-17 · Holder: Raymond Debbane · Percent: 7.2% · SCHEDULE 13G
• Filing 2026-08-14 · Reporting person: venBio Global Strategic Fund V, L.P. · Sole voting: 0 · Shared voting: 279,340 · Sole dispositive: 0 · Shared dispositive: 279,340 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 59,000 · Sole dispositive: 0 · Shared dispositive: 59,000 · SCHEDULE 13G, 2026-08-14
• Event date 2026-08-13 · Holder: Zhang Xiaofan · Percent: 0.6% · Shares: 162,452 · SCHEDULE 13G/A

Yarrow Bioscience, Inc. has 21 Schedule 13D or 13G filings on record since 2025-08-14. 11 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Yarrow Bioscience, Inc. and the warning signs.

See Yarrow Bioscience, Inc.'s free Snapshot Watch Yarrow Bioscience, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Yarrow Bioscience, Inc. and the records around it.

Yarrow Bioscience, Inc. elsewhere on the record

• Leadership changes Jul 2026
• Who owns it

Companies that share a holder

• venBio Global Strategic Fund V, L.P. also filed stake reports on 1 other company: ACHIEVE LIFE SCIENCES, INC. (Apr 2026)
• AI Biotechnology LLC also filed stake reports on 3 other companies: Latigo Biotherapeutics, Inc. (Nov 2026), OnKure Therapeutics, Inc. (Apr 2026), Zura Bio Limited (Mar 2026)
• Bellevue Group AG also filed stake reports on 6 other companies: Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026), Viridian Therapeutics, Inc. (May 2026)

Want the whole picture on Yarrow Bioscience, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Yarrow Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Yarrow Bioscience, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   22 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Yarrow Bioscience, Inc. by CUSIP 92941V407 and gives its principal executive office as 470 James Street, Suite 007, New Haven, CT 06513 (SCHEDULE 13G, 2026-10-07).

What the percentages are based on

As of July 27, 2026, and the date hereof, each of the Reporting Persons may be deemed to beneficially own approximately 9.99% of the shares of Common Stock outstanding.venBio Global Strategic Fund V, L.P., SCHEDULE 13G, 2026-08-14

As of September 14, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page.Raymond Debbane, SCHEDULE 13G, 2026-09-17

Source of funds (Item 3)

On July 27, 2026, a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into the Issuer with the Issuer continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the Merger, OrbiMed Private Investments X, LP ("OPI X") received 233,019 Shares and pre-funded warrants ("Warrants") to purchase 4,084,827 Shares, and OrbiMed Genesis Master Fund, L.P. ("Genesis") received 33,287 Shares and Warrants to purchase 583,545 Shares.Orbimed Advisors LLC, SCHEDULE 13D, 2026-08-05

Purpose of Transaction (Item 4)

AI Biotechnology LLC

The disclosure in Item 4 is hereby amended and supplemented by adding the following at the end thereof: On July 27, 2026, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025, as amended by Amendment No. 1 thereto on January 30, 2026, by and among VYNE Therapeutics Inc., Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of VYNE Therapeutics Inc., and Yarrow Bioscience, Inc., a Delaware corporation ("Pre-Merger Yarrow"), Yellow Merger Sub Corp. merged with and into Pre-Merger Yarrow, with Pre-Merger Yarrow continuing as a wholly owned subsidiary of VYNE Therapeutics Inc. and the surviving corporation of the merger (the "Merger"). In connection with the completion of the Merger, VYNE Therapeutics Inc. changed its name to Yarrow Bioscience, Inc. Prior to the consummation of the Merger, the Issuer effected a 1-for-50 reverse stock split of its Common Stock by filing a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which became legally effective on July 24, 2026 (the "Reverse Stock Split"). Upon the effectiveness of the Reverse Stock Split, every 50 shares of Common Stock issued and outstanding immediately prior thereto were automatically and without further action on the part of the Issuer or any holders of Common Stock combined into one share of Common Stock. No fractional shares were issued as a result of the Reverse …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-29; the filing has the rest

Orbimed Advisors LLC

This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-05; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Yarrow Bioscience, Inc.

Who owns Yarrow Bioscience, Inc.?

On this page, 11 holders' latest ownership filings report 5% or more of Yarrow Bioscience, Inc.: Logos Global Management LP (10.7%, Schedule 13G/A, filed 2026-08-07), Bellevue Group AG (10.6%, Schedule 13G, filed 2026-10-07), RTW Fund Group GP, LLC (9.99%, Schedule 13G, filed 2026-07-30), Perceptive Advisors LLC (9.99%, Schedule 13G, filed 2026-08-03) and JANUS HENDERSON GROUP Ltd. (9.99%, Schedule 13G, filed 2026-08-07); 6 more are listed above.

Who are the largest shareholders of Yarrow Bioscience, Inc.?

By the share each holder's latest filing reports, the largest holders of Yarrow Bioscience, Inc. on this page are Logos Global Management LP (10.7%), Bellevue Group AG (10.6%) and RTW Fund Group GP, LLC (9.99%).

When did Logos Global Management LP buy into Yarrow Bioscience, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Logos Global Management LP on this page is the Schedule 13G, filed 2026-08-04, reporting 9.9%; its latest, Schedule 13G/A filed 2026-08-07, reports 10.7%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Yarrow Bioscience, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Yarrow Bioscience, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Yarrow Bioscience, Inc. is mentioned again
• Find former Yarrow Bioscience, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes